Harvard Bioscience outlines 2026 guidance with 2%–4% revenue growth and high-margin focus following structural improvements (NASDAQ:HBIO)

Core Insights - Harvard Bioscience, Inc. (HBIO) projects a revenue growth of 2% to 4% for 2026, focusing on high-margin products following structural improvements made in 2025 [2] Management View - The company’s President and CEO, John Duke, emphasized that 2025 was a crucial year for foundation building, which included refinancing in December that extended debt maturity and reduced annual debt service to $5 million, resulting in a savings of $3 million [2]